DESENVOLVIMENTO E VALIDAÇÃO DE METODOLOGIAS PARA AVALIAÇÃO DE ETORICOXIBE POR CROMATOGRAFIA LÍQUIDA E ESPECTROMETRIA DE MASSAS / DEVELOPMENT AND VALIDATION OF METHODOLOGIES FOR THE EVALUATION OF ETORICOXIB BY LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY
AUTOR(ES)
Liberato Brum Junior
DATA DE PUBLICAÇÃO
2006
RESUMO
Etoricoxib is a non-steroidal anti-inflammatory drug, from the coxibs group, that represents a second-generation of COX-2 inhibitors, used for the treatment of arthritis and pain. The methodologies for the evaluation of etoricoxib in pharmaceutical products and plasma were developed and validated in the present work. The reversed-phase liquid chromatography (RP-LC) analysis was carried out using a Synergi fusion C18 column (150 mm x 4.6 mm), maintained at a controlled-ambient temperature. The mobile phase consisted of phosphoric acid 0.01 M, pH 3.0/acetonitrile (62:38, V/V), run at a flow rate of 1.0 mL/min with detection at 234 nm. The chromatographic separation was obtained within 7.0 min and it was linear in the concentration range of 0.02-150 g/mL. The liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated using a Luna C18 column (50 mm x 3.0 mm), maintained at 40 C and the mobile phase consisted of acetonitrile:water (95:5, V/V)/ 0.1% acetic acid (90:10, V/V), run at flow rate of 0.4 mL/min. The mass spectrometer, equipped with electrospray positive source, was used in multiple reaction monitoring mode (MRM), monitoring the transitions of 359.3>280.0 and 332.0>95.0, for etoricoxib and piroxicam (internal standard), respectively. The chromatographic separation was obtained within 2.0 min and it was linear in the concentration range of 1-5000 ng/mL. The procedures were validated evaluating parameters such as the specificity, linearity, precision, accuracy, robustness, limit of detection and limit of quantitation. Besides, for the bioanalytical method, the matrix effects, recovery and stability studies were also analyzed, giving results within the acceptable range. The proposed methods were applied for the analysis of pharmaceutical products, showing significant correlation (r=0.9999) of the results. Moreover, the liquid-liquid and solid phase extraction methods developed and optimized allowed high mean recoveries of etoricoxib and internal standard from the plasma samples. The procedures can be applied for the biovailability studies and for the quality control of pharmaceutical products.
ASSUNTO(S)
cromatografia líquida etoricoxib plasma humano human plasma produtos farmacêuticos validação etoricoxibe validation espectrometria de massas liquid chromatography mass spectrometry farmacia pharmaceutical products
ACESSO AO ARTIGO
http://coralx.ufsm.br/tede/tde_busca/arquivo.php?codArquivo=103Documentos Relacionados
- DESENVOLVIMENTO E VALIDAÇÃO DE METODOLOGIAS PARA AVALIAÇÃO DE EZETIMIBA POR CROMATOGRAFIA LÍQUIDA E ESPECTROMETRIA DE MASSAS
- DEVELOPMENT AND VALIDATION OF METHODOLOGY FOR THE EVALUATION OF RUPATADINE BY LIQUID CHROMATOGRAPHY AND CAPILLARY ELECTROPHORESIS
- DEVELOPMENT AND VALIDATION OF METHODOLOGY FOR THE EVALUATION OF FLUTICASONE BY LIQUID CHROMATOGRAPHY AND CAPILLARY ELECTROPHORESIS
- Development of analyrtical methods for determination of N-nitrosamines in shampoo samples by liquid chromatography coupled to diode array, electrochemical and mass spectrometry detecto
- DEVELOPMENT, VALIDATION AND APPLICATION FOR A SOLID PHASE MICROEXTRACTION AND LIQUID PHASE MICROEXTRACTION FOR DETERMINATION OF HUMAN HAIR BY CANNABINOIDS IN GAS CHROMATOGRAPHY MASS SPECTROMETRY COUPLING METHOD IN TANDEM